For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

MOTS-c: origin, structure and research history

Research Library › Mitochondrial & Coenzyme

MOTS-c is a naturally occurring 16-amino-acid peptide encoded by a short open reading frame inside the mitochondrial gene for 12S ribosomal RNA. It was described in 2015 by Changhan Lee, Pinchas Cohen and colleagues at the University of Southern California’s Leonard Davis School of Gerontology. As of 22 Oct 2026 it is not approved as a medicine anywhere; an FDA advisory committee voted 7–5 in July 2026 in favor of 503A compounding eligibility, and FDA has not issued a final decision.

Key facts

TypeNatural 16-amino-acid mitochondrial-derived peptide
Encoded byMitochondrial DNA, within the 12S rRNA gene
First described2015, Cell Metabolism (Lee, Cohen et al.); discovery dated to 2012 by CohBar
Developed byChanghan Lee and Pinchas Cohen, USC Leonard Davis School of Gerontology
Designed targetProposed: skeletal muscle, AMPK pathway (mouse studies); FDA lists molecular target as unknown
Regulatory status (Oct 2026)Not FDA-approved; removed from Category 2 (Apr 2026); PCAC voted 7–5 for 503A listing (Jul 2026), no final decision; named on WADA 2026 list (S4)

Who developed it

MOTS-c was identified by Changhan Lee and Pinchas Cohen at the University of Southern California’s Leonard Davis School of Gerontology, working with colleagues at UCLA and the U.S. National Institute on Aging. Their description appeared in Cell Metabolism in March 2015 [1].

Cohen also co-founded CohBar, a company built to develop drugs from mitochondrial-derived peptides. CohBar dates the discovery of MOTS-c to 2012 and later developed a modified analog, CB4211 [2].

What it was designed to target

MOTS-c is not an engineered molecule; it is a peptide the cell can make from its own mitochondrial genome. Its coding sequence sits inside the mitochondrial gene for 12S ribosomal RNA [1][3].

In the original mouse studies, MOTS-c was reported to act in skeletal muscle and to interact with the AMPK pathway, a cellular energy-sensing system. That remains a proposed mechanism. FDA’s 2026 evaluation states that the molecular target of MOTS-c is unknown, that the available efficacy data come only from animal and cell studies, and that laboratory tests show the peptide breaks down quickly in human blood [1][3].

Why it was created

The USC group was studying mitochondrial-derived peptides, small peptides encoded in mitochondrial DNA, as possible signals in metabolic regulation and aging. MOTS-c was originally investigated in mouse models of age-related and diet-related insulin resistance [1].

CohBar’s analog, CB4211, was designed to be more suitable as a drug candidate than the natural peptide and was taken into a small phase 1a/1b study in a research program on fatty liver disease and obesity [2].

Research timeline

  • 2012: Discovery of MOTS-c, according to CohBar [2].
  • 2015: Lee, Cohen and colleagues publish the first description in Cell Metabolism [1].
  • 2021: CohBar reports a phase 1a/1b study of the analog CB4211 [2].
  • 2023: CohBar suspends CB4211 development, citing an unsuitable formulation, and moves to dissolve the company [4][5].
  • Apr 2026: FDA removes MOTS-c from its Category 2 list of bulk substances [6].
  • May 2026: FDA publishes its 503A evaluation of MOTS-c [3].
  • Jul 2026: FDA’s Pharmacy Compounding Advisory Committee votes 7–5, with two abstentions, in favor of listing [7].

Regulatory status as of October 2026

As of 22 Oct 2026, MOTS-c is not approved as a medicine in any country. In April 2026 FDA removed it from Category 2, its list of nominated bulk substances raising significant safety concerns [6]. At a July 2026 meeting, the Pharmacy Compounding Advisory Committee (PCAC) voted 7–5, with two abstentions, to recommend adding MOTS-c to the 503A bulks list, against the recommendation of FDA staff [3][7]. FDA had issued no final decision as of mid-October 2026 [8][9].

FDA’s review found no published human studies of the natural peptide; human testing to date involved only the analog CB4211 [2][3][10]. On 14 October 2026 FDA sent an interim access policy on compounding certain peptides to the White House for review; its peptide list is not public [11].

MOTS-c is named on the 2026 World Anti-Doping Agency Prohibited List under S4 (metabolic modulators), prohibited at all times [12].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who discovered MOTS-c?

MOTS-c was described in 2015 by Changhan Lee, Pinchas Cohen and colleagues at the University of Southern California, with collaborators at UCLA and the National Institute on Aging.

Is MOTS-c FDA approved?

No. As of 22 Oct 2026 MOTS-c is not approved anywhere. An FDA advisory committee voted 7–5 in July 2026 to recommend it for the 503A compounding list, but FDA has not made a final decision.

Where does MOTS-c come from?

It is encoded in mitochondrial DNA, within the gene for 12S ribosomal RNA, which makes it a mitochondrial-derived peptide.

Has MOTS-c been studied in humans?

FDA’s 2026 review found no published human studies of natural MOTS-c. A modified analog, CB4211, was tested in a small phase 1a/1b study before its developer suspended the program in 2023.

Sources

  1. Lee C, Zeng J, Drew BG, et al., Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009 Link
  2. CohBar Inc. Press release on the Phase 1a/1b study of CB4211. 10 Aug 2021. Link
  3. US FDA, CDER. Evaluation of MOTS-c-related bulk drug substances for inclusion on the 503A Bulks List (briefing document). 11 May 2026. Link
  4. CohBar Inc. Form 10-Q, quarter ended 31 Mar 2023. SEC. Link
  5. CohBar Inc. Form 8-K (event date 6 Nov 2023). SEC. Link
  6. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 list. 16 Apr 2026. Link
  7. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  8. Faviero GF, Dresser JC, Asebey EJ (Frier Levitt). FDA PCAC peptide vote: what the 503A recommendations mean. 17 Sep 2026 (modified 15 Oct 2026). Link
  9. Frier Levitt. Trump Administration's proposed peptide enforcement discretion policy: what compounding pharmacies and peptide suppliers need to know. 14 Oct 2026. Link
  10. AbuDagga A (Public Citizen). Testimony before FDA's Pharmacy Compounding Advisory Committee regarding placing MOTS-c on the 503A Bulks List. 23 Jul 2026. Link
  11. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  12. World Anti-Doping Agency. 2026 Prohibited List (in force 1 Jan 2026): S4.4.1. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top